A.B. Benson

862 total citations
29 papers, 612 citations indexed

About

A.B. Benson is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A.B. Benson has authored 29 papers receiving a total of 612 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Surgery and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A.B. Benson's work include Gastric Cancer Management and Outcomes (10 papers), Colorectal Cancer Treatments and Studies (9 papers) and Colorectal and Anal Carcinomas (6 papers). A.B. Benson is often cited by papers focused on Gastric Cancer Management and Outcomes (10 papers), Colorectal Cancer Treatments and Studies (9 papers) and Colorectal and Anal Carcinomas (6 papers). A.B. Benson collaborates with scholars based in United States, Canada and Australia. A.B. Benson's co-authors include Mark S. Talamonti, D.G. Haller, Richard M. Hansen, D C Tormey, Tom Anderson, Louise Ryan, Edward J. Quebbeman, Lynn M. Schuchter, E. Kaplan and Henry Wagner and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

A.B. Benson

28 papers receiving 591 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A.B. Benson United States	11	330	222	222	116	66	29	612
Byung Woog Kang South Korea	15	331 1.0×	324 1.5×	182 0.8×	167 1.4×	43 0.7×	43	663
Antonello Quadri Italy	7	325 1.0×	67 0.3×	170 0.8×	151 1.3×	93 1.4×	12	557
Kyu-pyo Kim South Korea	12	473 1.4×	268 1.2×	132 0.6×	112 1.0×	63 1.0×	18	654
Jan Willem de Groot Netherlands	12	330 1.0×	134 0.6×	153 0.7×	185 1.6×	38 0.6×	55	629
Annett Maderer Germany	12	254 0.8×	149 0.7×	161 0.7×	96 0.8×	77 1.2×	25	440
Petros Giovanis Italy	12	236 0.7×	98 0.4×	147 0.7×	112 1.0×	28 0.4×	28	534
Laura Milesi Italy	9	256 0.8×	77 0.3×	95 0.4×	132 1.1×	56 0.8×	16	475
Dae–Yong Hwang South Korea	16	340 1.0×	162 0.7×	195 0.9×	130 1.1×	188 2.8×	52	684
Yu‐Li Su Taiwan	15	247 0.7×	218 1.0×	172 0.8×	147 1.3×	67 1.0×	75	637
H Tomoda Japan	10	180 0.5×	144 0.6×	115 0.5×	60 0.5×	76 1.2×	34	413

Countries citing papers authored by A.B. Benson

Since Specialization

Citations

This map shows the geographic impact of A.B. Benson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.B. Benson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.B. Benson more than expected).

Fields of papers citing papers by A.B. Benson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.B. Benson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.B. Benson. The network helps show where A.B. Benson may publish in the future.

Co-authorship network of co-authors of A.B. Benson

This figure shows the co-authorship network connecting the top 25 collaborators of A.B. Benson. A scholar is included among the top collaborators of A.B. Benson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.B. Benson. A.B. Benson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lieu, Christopher H., et al.. (2024). 633P First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors. Annals of Oncology. 35. S504–S504.

Blarigan, Erin L. Van, Fang‐Shu Ou, Donna Niedzwiecki, et al.. (2018). Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiology Biomarkers & Prevention. 27(10). 1227–1230. 15 indexed citations

Bleiberg, Harry, Genevieve Decoster, Aimery de Gramont, et al.. (2017). A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. Annals of Oncology. 28(5). 922–930. 10 indexed citations

Benson, A.B., et al.. (2015). Abstract A24: Neuropilin 1 (NRP1) as a potential biomarker for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in metastatic colorectal cancer (mCRC): Post-hoc biomarker analysis of BATON-CRC phase 2 trial. Molecular Cancer Therapeutics. 14(12_Supplement_1). A24–A24. 2 indexed citations

Chakravarthy, A. Bapsi, Paul J. Catalano, David I. Rosenthal, et al.. (2011). A Phase II Trial of Neoadjuvant Paclitaxel/Cisplatin Chemotherapy followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/leucovorin (FU/LV) for Gastric Cancer (ECOG E7296). International Journal of Radiation Oncology*Biology*Physics. 81(2). S67–S67. 1 indexed citations

Kleinberg, Lawrence, Paul J. Catalano, Michael K. Gibson, et al.. (2010). ECOG 2205: A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy (CRT) (IMRT permitted) with Oxaliplatin (O) and Infusional 5-Fluorouracil (5FU) Plus Cetuximab (C225) in Patients with Operable Adenocarcinoma of the Esophagus: High Risk of Post-op Adult Respiratory Distress Syndrome (ARDS). International Journal of Radiation Oncology*Biology*Physics. 78(3). S72–S72. 8 indexed citations

Landry, Jerome C., et al.. (2009). Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer: ECOG 3204. International Journal of Radiation Oncology*Biology*Physics. 75(3). S27–S28. 3 indexed citations

Luketich, James D., Arjun Pennathur, Paul J. Catalano, et al.. (2009). Results of a phase II multicenter study of minimally invasive esophagectomy (Eastern Cooperative Oncology Group Study E2202). Journal of Clinical Oncology. 27(15_suppl). 4516–4516. 24 indexed citations

Yao, James C., A.B. Benson, Anne Thomas, et al.. (2008). A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology. 63(2). 363–370. 50 indexed citations

10.

Kleinberg, Lawrence, et al.. (2008). Outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) Randomized Phase II Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/RT or Irinotecan/Cisplatin/RT in Endoscopy with Ultrasound (EUS) Staged Esophageal Adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics. 72(1). S72–S72. 3 indexed citations

11.

Benson, A.B.. (2007). Epidemiology, disease Progression, and Economic Burden of Colorectal Cancer. Journal of Managed Care Pharmacy. 13(6 Supp C). 5–18. 108 indexed citations

12.

Regine, William F., Kathryn Winter, Ross A. Abrams, et al.. (2006). 42. International Journal of Radiation Oncology*Biology*Physics. 66(3). S23–S24. 2 indexed citations

13.

Liebes, Leonard, David T. Levy, Elizabeth Poplin, et al.. (2006). Gemcitabine (G) plamsa and intracellular pharmacokinetics in E6201: Greater metabolite levels using fixed dosing rate (FDR) delivery. Journal of Clinical Oncology. 24(18_suppl). 2024–2024. 1 indexed citations

14.

Landry, Jerome C., Paul J. Catalano, John Hoffman, et al.. (2006). 2111. International Journal of Radiation Oncology*Biology*Physics. 66(3). S272–S272. 3 indexed citations

15.

Johnston, P. G., A.B. Benson, Paul Catalano, et al.. (2005). The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: An Intergroup combined analysis. Journal of Clinical Oncology. 23(16_suppl). 3510–3510. 6 indexed citations

16.

Talamonti, Mark S., et al.. (2001). Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncology Reports. 8(3). 497–500. 28 indexed citations

17.

Hansen, Richard M., Louise Ryan, Tom Anderson, et al.. (1996). Phase III Study of Bolus Versus Infusion Fluorouracil With or Without Cisplatin in Advanced Colorectal Cancer. JNCI Journal of the National Cancer Institute. 88(10). 668–674. 102 indexed citations

18.

Lipsitz, Stuart R., Henry Wagner, E. Kaplan, et al.. (1996). Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): An eastern cooperative oncology group study. International Journal of Radiation Oncology*Biology*Physics. 35(4). 745–749. 98 indexed citations

19.

Martenson, James A., S. Lipsitz, Hans‐Joachim Wagner, et al.. (1995). 34 phase II trial of radiation therapy, 5-fluorouracil and cisplatin in patients with anal cancer. International Journal of Radiation Oncology*Biology*Physics. 32. 158–158. 4 indexed citations

20.

Neuberg, Donna, et al.. (1995). 38 Neoadjuvant chemotherapy plus concurrent chemotherapy and high dose radiation for squamous cell cancer of the esophagus — A preliminary analysis of intergroup trial 0122 (ECOG PE-289/RTOG 9012). International Journal of Radiation Oncology*Biology*Physics. 32. 160–160. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact